Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes

NCT01601990 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Placebo group(once daily)
DRUG: LC15-0444 50mg qd

Sponsor

LG Life Sciences